Antitumor activity of imatinib mesylate in neuroblastoma xenografts

Cancer Letters

Volumn 228, Issue 1-2, 2005, Pages 211-219

  Meco, Daniela ^a   Riccardi, Anna ^a   Servidei, Tiziana ^a   Brueggen, Josef ^b   Gessi, Marco ^a   Riccardi, Riccardo ^a   Dominici, Carlo ^c,d,e  

^a CATHOLIC UNIVERSITY   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

c kit; Imatinib mesylate; Neuroblastoma; PDGFR ; Receptor tyrosine kinases; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; CGP 74588; CPG 74588; DRUG METABOLITE; IMATINIB; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER GRAFT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

EID: 23944524789     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.02.054     Document Type: Review

References (26)

1. G.M. Brodeur Neuroblastoma: biological insights into a clinical enigma Nat. Rev. Cancer 3 2003 203 216
2. B. De Bernardi, B. Nicolas, L. Boni, P. Indolfi, M. Carli, and L. Cordero di Montezemolo Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Cooperative Group for Neuroblastoma J. Clin. Oncol. 21 2003 1592 1601
3. D. Fabbro, S. Ruetz, E. Buchdunger, S.W. Cowan-Jacob, G. Fendrich, and J. Liebetanz Protein kinases as targets for anticancer agents: from inhibitors to useful drugs Pharmacol. Ther. 93 2002 79 98
4. A. Bennasroune, A. Gardin, G. Aunis, G. Cremel, and P. Hubert Tyrosine kinase receptors as attractive targets of cancer therapy Crit. Rev. Oncol. Hematol. 50 2004 23 38
5. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohono, G.M. Segal, and S. Fanning Effect of a selective inhibitor of the ABL tyrosine kinase on the growth of Bcr-Abl positive cells Nat. Med. 2 1996 561 566
6. E. Buchdunger, J. Zimmermann, H. Mett, T. Meyer, M. Muller, and B.J. Druker Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivate Cancer Res. 56 1996 100 104
7. K. Mizutani, Y. Tamada, K. Hara, T. Tsuzuki, H. Saeki, and K. Tamaki Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans Br. J. Dermatol. 151 2004 235 237
8. C.L. Corless, J.A. Fletcher, and M.C. Heinrich Biology of gastrointestinal stromal tumors J. Clin. Oncol. 22 2004 3813 3825
9. P.S. Cohen, J.P. Chan, M. Lipkunsakaya, J.L. Biedler, and R.C. Seeger Expression of stem cell factor and c-kit in human neuroblastoma Blood 84 1994 3465 3472
10. S. Uccini, O. Mannarino, H.P. McDowell, U. Pauser, R. Vitali, and P.G. Natali Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors Clin. Cancer Res. 11 2005 380 389
11. T. Matsui, K. Sano, T. Tsukamoto, M. Ito, T. Takaisci, and H. Nakata Human neuroblastoma cells express alpha and beta platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signalling J. Clin. Invest. 92 1993 1153 1160
12. S. Lev, J.M. Blechman, D. Givol, and Y. Yarden Steel factor and c-kit proto-oncogene: genetic lessons in signal transduction Crit. Rev. Oncog. 5 1994 141 168
13. W.J. La Roschelle, M. Jeffers, J.R. Corvalan, X.C. Jia, X. Feng, and S. Vanegas Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer Cancer Res. 62 2002 2468 2473
14. R. Vitali, V. Cesi, M.R. Nicotra, H.P. McDowell, A. Donfrancesco, and O. Mannarino c-kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571 Int. J. Cancer 106 2003 47 52
15. K. Beppu, J. Jaboine, M.S. Merchant, C.L. Mackall, and C.J. Thiele Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression J. Natl Cancer Inst. 96 2004 46 55
16. E. Buchdunger, C.L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, and B.J. Druker Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J. Pharmacol. Exp. Ther. 295 2000 139 145
17. S. Scarpa, C. Dominici, P. Grammatico, G. Del Porto, G. Raschellá, and M. Castello Establishment and characterization of a human neuroblastoma cell line Int. J. Cancer 43 1989 645 651
18. (2)-terminal kinase through MKK7 in human thyroid cells Oncogene 20 2001 989 996
19. E. Buchdunger, T. O'Reilly, and J. Wood Pharmacology of imatinib (STI571) Eur. J. Cancer 38 Suppl. 2002 S28 S36
20. M. Carroll, S. Ohno-Jones, S. Tamura, E. Buchdunger, J. Zimmermann, and N.B. Lydon CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins Blood 90 1997 4947 4952
21. D.A. Tuveson, N.A. Willis, T. Jacks, J.D. Griffin, S. Singer, and C.D. Fletcher STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications Oncogene 20 2001 5054 5058
22. M.S. Merchant, C.W. Woo, C.L. Mackall, and C.J. Thiele Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity J. Natl Cancer Inst. 94 2002 1673 1679
23. B.J. Druker Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work? J. Natl Cancer Inst. 94 2002 1660 1661
24. H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, and F. Giles High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukaemia Blood 103 2004 2873 2878
25. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, and J.M. Ford Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
26. C. Borg, M. Terme, J. Taieb, C. Menard, C. Flament, and C. Robert Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects J. Clin. Invest. 114 2004 379 388